REG - Aptamer Group PLC - Agreement with global life sciences leader

AptamerAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nRSY2583Oa&default-theme=true

RNS Number : 2583O  Aptamer Group PLC  25 June 2025

 

25 June 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Development and licensing agreement with global life sciences leader

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce a new development and licensing agreement with an
established global company in the life sciences and diagnostics sector, part
of a major multinational conglomerate (the "Partner").

 

Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for
use in immunohistochemistry (IHC) assays and diagnostic kits, leveraging its
proprietary Optimer®-Fc platform, which produces aptamer binders with an
antibody Fc-tag optimised for IHC workflows. The Partner will fully fund the
development work, which is expected to be completed within a 12-month
timeline, for an undisclosed sum. Subject to development and validation, the
Optimer®-Fc reagent is anticipated to be incorporated into commercial IHC
kits, with a product launch expected within the current calendar year.

 

The agreement includes a commercial licensing arrangement, under which Aptamer
will receive royalties of 2% on net sales of all assay kits containing the
licensed Optimer®-Fc reagent, subject to standard minimum royalty
commitments. The kits are expected to be distributed through recognised global
channels specialising in life sciences research products.

 

This partnership strengthens Aptamer's recurring revenue potential and
supports its strategy to expand the application of its Optimer platform in
high-value life sciences markets. The collaboration with a globally respected
industry leader underscores the commercial potential and technical
capabilities of Aptamer's Optimer®-Fc technology for advanced diagnostic
applications.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:

 

"We are pleased to collaborate with a leading global life sciences company to
develop this Optimer®-Fc reagent for IHC applications. The royalty structure
and fully funded development provide a clear path to revenue generation and
validate the strength of our Optimer platform. This agreement enhances our
portfolio of royalty-generating assets and supports our mission to deliver
innovative solutions to the life sciences industry."

 

Certain details of the agreement, including specific financial terms and the
identity of the Partner, are commercially sensitive and have not been
disclosed at this stage. The Company will provide updates on material
developments as appropriate.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.

Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAXKLALFSEFA